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Abstract
Background: Heart failure is a major cause of morbidity and mortality in society. Current medical therapy centres
on neurohormonal modulation with angiotensin converting enzyme inhibitors and b-blockers. There is growing
evidence for the use of metabolic manipulating agents as adjunctive therapy in patients with heart failure. We aim
to determine the effect of perhexiline on cardiac energetics and alterations in substrate utilisation in patients with
non-ischaemic dilated cardiomyopathy.
Methods: A multi-centre, prospective, randomised double-blind, placebo-controlled trial of 50 subjects with non-
ischaemic dilated cardiomyopathy recruited from University Hospital Birmingham NHS Foundation Trust and Cardiff
and Vale NHS Trust. Baseline investigations include magnetic resonance spectroscopy to assess cardiac energetic
status, echocardiography to assess left ventricular function and assessment of symptomatic status. Subjects are
then randomised to receive 200 mg perhexiline maleate or placebo daily for 4 weeks with serum drug level
monitoring. All baseline investigations will be repeated at the end of the treatment period. A subgroup of patients
will undergo invasive investigations with right and left heart catheterisation to calculate respiratory quotient, and
mechanical efficiency. The primary endpoint is an improvement in the phosphocreatine to adenosine triphosphate
ratio at 4 weeks. Secondary end points are: i) respiratory quotient; ii) mechanical efficiency; iii) change in left
ventricular (LV) function.
Trial Registration: ClinicalTrials.gov: NCT00841139
ISRCTN: ISRCTN2887836
Background
Despite recent advances in the treatment of heart failure
(HF), it remains a condition with significant morbidity
and mortality having a 5 year mortality rate that rivals
most cancers [1]. In the developed world, heart failure
affects 1-2% of the general population [2], causing about
5% of all adult hospital admissions, and complicating a
further 10-15% [3]. Current pharmacological therapy
centres on the management of symptoms with diuretics
and neurohormonal modulation with angiotensin con-
verting enzyme inhibitors and b-blockers. Energy defi-
ciency plays an important role in the pathophysiology of
HF and is held to be a promising target for HF therapy.
Numerous studies support the finding of decreased
cardiac energy levels and flux as a consistent feature of
HF [4,5].
The main determinants of cardiac energetics and
energy availability are substrate utilisation. The normal
heart relies mainly on fatty acids for its energy require-
ments, accounting for up to 70% of the total energy
requirement in the fasting state [6]. Glucose and other
carbohydrates such as lactate make up much of the
remainder. Mitochondrial phosphorylation represents the
major route of energy generation. The heart is a meta-
bolic omnivore and can adapt to utilise various substrates
depending on requirements, but each substrate varies in
its energy cost. Fatty acid oxidation (FAO) requires
greater oxygen for a given quantity of adenosine tripho-
sphate (ATP) synthesis than the use carbohydrates. In
HF, there is typically a down regulation of fatty acid
metabolism with preserved or increased glucose uptake,
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but often a relative block of entry of pyruvate in to the
tricarboxylic acid cycle (TCA cycle).
These metabolic changes contribute to the energy star-
vation state found in heart failure of all aetiologies. Phos-
phorus-31 (P-31) magnetic resonance spectroscopy
(MRS) is used to non-invasively estimate ATP and phos-
phocreatine concentration and the PCr/ATP ratio. Phos-
phocreatine is an important short-tem energy store that
maintains a high phosphorylation potential under condi-
tions of rapid increased energy demand such as exercise.
ATP levels are maintained at steady concentration to
maintain energy for muscle contraction and normal cel-
lular function. The myocardial PCr/ATP ratios is reduced
in HF and correlates with New York Heart Association
(NYHA) class [5].
Perhexline maleate is a metabolic modulating agent
that gained popularity in the 1970’s as an antianginal
therapy until it was linked to both peripheral neuropathy
[7] and hepatotoxicity [8]. It has since been shown that
the risk of toxicity can be dramatically reduced by main-
taining plasma concentrations in an established normal
range of between 0.15 and 0.6 mg/L [9]. In the isolated
rat heart, perhexiline acts, at least in part, by shifting
myocardial substrate utilisation from fatty acids to carbo-
hydrates through the inhibition of carnitine palmitoyl-
transferase-1 (CPT-1) and, to a lesser extent, carnitine
palmitoyltransferase-2 (CPT-2). These mitochondrial
enzymes act to facilitate the entry of medium and long
chain fatty acids into the myocytes as their main energy
source. Their inhibition causes a reciprocal increase in
glucose and lactate utilisation and thus an improvement
in myocardial efficiency and energy status by forcing the
omnivorous myocytes to metabolise carbohydrate and
reduce the net oxygen consumption.
A growing body of studies support the use of P-31
MRS to measure this improvement in myocardial ener-
getics as a response to treatment. Fragasso et al [10] have
demonstrated an increase in cardiac PCr/ATP ratio with
the metabolic modulating agent trimetazidine in subjects
with heart failure. Our group has recently shown an
improvement in cardiac energetics using perhexiline in
patients with hypertrophic cardiomyopathy [11].
Methods
Hypothesis
Treatment with perhexiline increases cardiac PCr/ATP
ratio, increases cardiac respiratory quotient (indicating
relatively greater carbohydrate utilisation), and improves
LV mechanical efficiency and left ventricular function in
patients with dilated cardiomyopathy.
Study Design
This is a multicentre prospective, randomised, double-
blind, placebo-controlled trial of 50 subjects with dilated
cardiomyopathy (defined as an ejection fraction (EF)
<40% in the absence of evidence of coronary artery dis-
ease) who are stable on conventional heart failure ther-
apy. Inclusion and exclusion criteria are detailed in
Table 1.
Baseline Studies
All patients will undergo a baseline visit (see flowchart -
Figure 1) during which the following will be performed;
i) detailed review of past medical history, drug history
and tobacco and alcohol consumption; ii) clinical exami-
nation of all systems; iii) assessment of NYHA class
from history; iv) completion of a Minnesota Living with
Heart Failure (MLWHF) questionnaire; v) measurement
of height and weight; vi) 12-lead electrocardiogram
(ECG); vii) office brachial blood pressure and heart rate
measurement following 15 minutes rest; viii) collection
of fasting serum and plasma for haematological and bio-
chemical analysis including glucose and liver function
tests; ix) storage of serum and plasma at -80°c for future
assay of biomarkers of heart failure such as pro-terminal
brain natriuretic peptide (BNP); x) transthoracic echo-
cardiography to determine left ventricular size and func-
tion; xi) cardiac magnetic resonance spectroscopy to
determine the cardiac PCr/ATP ratio;
Baseline tests will be repeated in full after completing
one month of treatment with perhexiline or placebo. A
willing subgroup of patients will undergo right and left
heart catheterisation for invasive haemodynamic mea-
surements and cross heart sampling. Those subjects tak-
ing part in the invasive subgroup will also undergo
cardiac magnetic resonance imaging (CMR) for accurate
estimation of left ventricular cardiac mass.
Female subjects of child-bearing potential will be
excluded from the study.
Table 1 Inclusion and exclusion criteria
Inclusion Criteria
Non-ischaemic, dilated cardiomyopathy
Symptomatic despite optimally-tolerated medical therapy
Impaired left ventricular systolic function (LVEF < 40%) as assessed by
resting echocardiography
Exclusion Criteria
History of liver disease or liver function test measurements greater than
twice the upper normal limit
Concomitant use of amiodarone, quinidine, haloperidol or selective
serotonin re-uptake inhibitors that inhibit the CYP2D6 enzyme
Pre-existing evidence of peripheral neuropathy
Women of child bearing potential
Patients with any contraindication to magnetic resonance imaging such
as an implantable cardiac device or claustrophobia
Obesity (BMI > 35)
Obstructive sleep apnoea
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Cardiac Magnetic Resonance Spectroscopy
Cardiac high-energy phosphate metabolism will be mea-
sured using P-31 MRS on a 3-Tesla Philips (Philips
Healthcare, Reigate, Surrey) Achieva whole-body magnet
using a linearly polarized transmit and receive P-31 coil
with a diameter of 14 cm. Localization will be achieved
by image selected in-vivo spectroscopy (ISIS) volume
selection. The participants will be positioned supine with
the coil directly over the precordium. The coil will be
secured in place by straps around the upper body and
coil. The participants will then be positioned inside the
magnet with the center of the coil at the isocenter of the
magnet. Survey images will be obtained to check the
position of the coil. The subjects and/or the coil will be
repositioned if required to ensure that the distance
between coil and septum and apex of the heart is
minimized and maximize signal strength. Localized itera-
tive 1st order shimming will be performed including the
entire heart using the unsuppressed water signal acquired
with the body coil as reference. The shimming process
involves an automated Hydrogen-1 spectral acquisition
to test the quality of the shim that is expressed as a full
width at half maximum (FWHM). This is repeated until
a FWHM of less than 40 Hz is achieved. A short axis
cine scan will be acquired to calculate the trigger delay
for ECG triggering and to check quality of shimming and
F0 determination. The trigger delay will be calculated
such that the spectra is acquired in the diastolic period
when the heart is a still as possible. The 3-dimensional
ISIS voxel of acquisition will be planned to include most
of the septum and apex of the heart within the shimmed
area. Care will be taken to minimize blood contamination
Figure 1 Summary of study timeline. Following baseline investigations, 50 patients will be randomised to recieve 200 mg of perhexiline or
matched placebo for one month. At one month all baseline tests will be repeated and a subgroup will undergo cardiac catheterisation.
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from the right ventricle, liver and skeletal muscle as
much as possible. The voxel size will be kept constant at
89.54 ml (44 × 55 × 37 mm3) to allow comparisons
between different subjects and scans. Following this the
P-31 spectrum will be acquired with a repetition time of
10000 ms and 512 averages. A repetition time of 10000
ms has found to be optimal for adequate reduction of
saturation effects without increasing the scan time
greatly. The total scan time will be 23 minutes. The spec-
tra will be analyzed and quantified on the java based
Magnetic Resonance User Interface (jMRUI) software.
Post-processing will be performed with 15 Hz Gaussian
line broadening and Fourier transformation. Phase cor-
rection will be performed with PCr peak as the reference
peak. Quantification will be performed with AMARES
(Advanced Method for Accurate, Robust and Efficient
Spectral fitting), time domain fitting program, which
involves selecting peaks and defining their line width
[12]. The concentrations of PCr, ATP (g, a and b) and
2,3-diphosphoglycerate (2,3-DPG) will then be calculated
as the area under the peaks. PCr/ATP ratio will be deter-
mined after correcting the g ATP peak for blood contam-
ination as described previously based on the quantity of
2,3-DPG in the derived spectrum [13]. A single, blinded
operator experienced in the technique will perform
analysis.
Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging will be performed
on the same 3 Tesla Philips Achieva system using a car-
diac coil with patients in the supine position. Serial con-
tiguous short axis cines will be piloted from the vertical
long axis and horizontal long axis images using standard
manufacturer supplied sequences. Analysis will be per-
formed offline (Philips ViewForum Ver 4.1) by a single
blinded observer for the assessment of ventricular
volumes, ejection fraction and left ventricular mass.
Echocardiography
A standard transthoracic echocardiogram (Vivid 7, GE
Vingmed Ultrasound, Horten, Norway) will be performed
with the subject in the left lateral decubitus position by a
single experienced echocardiographer using second har-
monic imaging and an M3S multi-frequency transducer.
All parameters will be measured in triplicate and aver-
aged as per the recommendations of the American
Society of Echocardiography [14]. Analysis will be per-
formed offline by a single blinded observer using an
EchoPAC workstation (GE Vingmed Ultrasound, Horten,
Norway). Ventricular dimensions, wall thickness, cham-
ber volume, stroke volume and ejection fraction will be
determined by standard methods [15]. Resting left ventri-
cular diastolic function will be determined using standard
techniques [16]. Peak systolic (S’), early diastolic (E’) and
late diastolic (A’) mitral annular velocities will be mea-
sured at end expiration at the septal, lateral, inferior and
anterior left ventricular walls with real time pulsed wave
tissue Doppler [17].
Greyscale images for 2-dimensional left ventricular
strain will be acquired in cine-loop format in triplicate
from the apical 4-, 2- and 3-chamber views and paraster-
nal short axis views at basal, papillary and apical ventri-
cular levels at end expiration at frame rates >70 Hz for
offline analysis using commercially available software
(Speqle Tracking, GE Healthcare, United Kingdom). The
endocardial border will be manually tracked at end-sys-
tole and the software generates a region of interest over
the myocardium. This enables frame-to-frame tracking of
ultrasonic speckles that change position according to sur-
rounding tissue motion throughout the length of the car-
diac cycle. Peak systolic velocities, strain, strain rate,
rotation and twist will be measured for each myocardial
segment in triplicate and averaged.
Invasive testing
Patients will undergo cardiac catheterisation via the
femoral artery and either the femoral or internal jugular
vein following appropriate consent. A 7F sheath will be
placed in the vein and artery. A Cordis-Webster (Cordis
Webster, Inc., Baldwin Park, CA, USA) 7F coronary sinus
(CS) thermodilution catheter will be guided into the cor-
onary sinus and 50/50 saline/contrast injections will
allow visualisation and confirmation of its position within
the right atrium and CS. All catheters will be calibrated
prior to utilisation. The catheter is connected to both a
Medtronic (Medtronic Inc., 7000 Central Avenue NE,
MN, USA) temporary pacemaker 5348 and to a specia-
lised Wheatstone bridge coupled to a bank of isolated
direct coupled bioamplifiers (Coulbourn Instruments,
Whitehall, PA). The output is subsequently digitised
using a Dataq DI720 data acquisition system and both
displayed and stored on a laptop computer using Windaq
software (Dataq, Akron, OH). The atria will then be
paced via electrodes on the catheter in the coronary
sinus.
A 7F dual-field conductance catheter (CA-71103-PL
catheter, CD Leycom, The Netherlands) will then guided
via the femoral artery sheath through the aortic valve and
positioned within the left ventricle. Blood samples will
then be taken from the left ventricle and CS for cross
heart substrate analysis prior to the administration of
heparin. The atria will then be paced at a rate just above
baseline to ensure a steady rate. The conductance catheter
allows continuous and simultaneous sampling of pressure
and volume at 4 ms intervals, allowing the acquisition of
pressure-volume loops in real-time. CS thermodilution
runs will be performed in triplicate (with an average of 3
runs used for analysis). Samples will then be taken for
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oxygen and carbon dioxide measurement. Oxygen mea-
surement will be performed using a Bayer Rapidlab 800
series blood gas analyser (Bayer Healthcare LLC, East
Walpole, MA, USA). Carbon dioxide measurement will be
performed by mass spectrometry by the University of Bri-
mingham using a Finnigan MAT DeltaplusX mass spectro-
meter. PV loops will be acquired from the left ventricle
with a CFL-512 system (CD Leycom), which allows further
offline analysis (CircLab, Leiden University, The Nether-
lands) for determination of left ventricular stroke work
(LVSW), mechanical efficiency, dp/dtmax, dp/dtmin, and
Tau (rate of active relaxation).
The steady heart rate will allow for accurate assess-
ment of per beat myocardial oxygen consumption. All
of this subgroup will have had CMR studies for accurate
assessment of cardiac mass and thus permit correction
for myocardial mass.
Respiratory quotient (RQ) is a unitless value found by
dividing the amount of eliminated CO2 by the O2 con-
sumed [1].
RQ = CO2 eliminated/O2 consumed (1)
Mechanical efficiency (ME) can be calculated by divid-
ing work output by work input giving another dimen-
sionless value or percentage [2].
ME = Work output/Work input (2)
Work input can be calculated from myocardial oxygen
consumption measurements according to the Fick prin-
ciple by multiplying coronary sinus blood flow by the
ateriovenous oxygen content difference [18]. To be used
in the above equation the caloric equivalent of 1 mL of
O2 is ≈20J will be used [19].
External work will be estimated from measurements
taken from the PV loops acquired from the left ventri-
cle. 1 mmHg × mL equates to 1.33 × 10-4 J for the pur-
poses of calculating ME [19].
Randomisation and Drug Monitoring
Following baseline investigations ensuring normal liver
function tests, participants will be randomised by com-
puter to commence with perhexiline 200 mg oral daily
or an identical placebo for one month (Figure 1). Ran-
domisation will be done in a 50:50 ratio of perhexiline:
placebo in blocks of 10.
At one week duration, all patients will have a blood
sample taken for serum perhexiline level with the
researcher blinded to the subject’s treatment allocation.
This level will be evaluated by a doctor unblinded to the
subject’s treatment allocation. The dosage of perhexiline
will be adjusted according to the accepted dosing proto-
col (Table 2). An equal number of dummy dose
adjustments will be made to those patients on placebo
to help to maintain blinding.
At the end of one month of therapy, patients will
undergo a repeat of baseline investigations and a further
perhexiline level will be taken to ensure therapeutic
levels were achieved and compliance maintained.
Endpoints
The primary end point of the study will be an increase
in the PCr/ATP ratio as assessed by MRS after 4 weeks
of treatment. This end point has been used in previous
studies and is associated with symptomatic class and
mortality in heart failure [20]. Secondary endpoints are:
i) respiratory quotient; ii) mechanical efficiency; iii)
change in LV function.
Planned Statistical Analysis
Comparisons will be performed between the groups at
baseline and after the 4 week treatment. The normality
of distribution of all continuous variables will be deter-
mined using a normality plot and the Kolmogorov-Smir-
nov test. Normally distributed variables will be analysed
using unpaired t-tests, c2 or repeated measures analysis
or variance. Variables not normally distributed will be
log transformed prior to analysis to achieve normal dis-
tribution or, if this is not achieved, analysed by Mann-
Whitney U or Kruskal-Wallis tests.
Analysis will be by intention-to-treat. A p-value of <
0.05 will be considered statistically significant.
Sample size calculations were based on the primary
end point of change in PCr/ATP ratio after 4 weeks of
treatment. Pilot work from our group using the same
MRS technique and perhexiline revealed a 0.4 improve-
ment in PCr/ATP ratio in the treatment group by com-
paring means. The response was normally distributed
with a standard deviation of 0.5. Using this data, 26 sub-
jects in each arm will provide at least 80% power of
detecting a 0.4 change in PCr/ATP ratio using a two-
tailed t-test at the 5% significance level. Recruiting 50
patients will allow for withdrawal, drop out or incom-
plete data.










>2.00 Cease for 1 week and start 50 mg
alternate days
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Monitoring and Safety Assessments
When perhexiline levels are unmonitored, it has been
associated with both hepatotoxicity and peripheral neu-
ropathy. All patients will be screened both clinically and
biochemically for any sign of these conditions. Perhexi-
line also lowers serum glucose levels. Patients who are
diabetic will be made aware that the medication may
cause hypoglycaemic and they will be instructed make
frequent blood sugar measurements when starting the
study. Perhexiline levels will be tested at one week and
at the end of the study as outlined above.
All adverse events, including serious adverse events
(SAEs), will be recorded and followed up for the dura-
tion of the study or until resolution. Assessment of
adverse events will be performed by study investigators.
All SAEs will be graded and reported to the sponsor.
Any suspected unexpected serious adverse reactions will
be reported to the sponsor, ethics committee and the
Medicines and Healthcare Products Regulatory Agency.
This study has been reviewed and approved by the
South Birmingham Research Ethics Committee. Written
informed consent will be obtained from all study
participants.
Study Limitations
The study is powered for the primary endpoint (an
increase in PCr/ATP ratio assessed after 4 weeks of
treatment). It is accepted that the study is likely to be
underpowered for the secondary endpoint of improve-
ment in LV function. Nonetheless, a similar sized study
using perhexiline in heart failure showed a dramatic,
absolute increase in ejection fraction of 10% after 2
months of treatment [21]. This improvement had a
standard deviation of approximately 10%. Assuming a
similar distribution in this study, our sample size should
allow us to detect an 8% improvement in ejection frac-
tion, which is comparable to that demonstrated in a
recent meta-analysis highlighting the effect of trimetazi-
dine (another metabolic modulating agent) on ejection
fraction in non-ischaemic heart failure [22].
No similar invasive work of this nature has been per-
formed in human heart failure to allow an accurate
power calculation for this component of the trial.
Discussion
The finding that perhexiline improves cardiac energetics
by an increase in the PCr/ATP ratio would be an impor-
tant contribution to support the future work of meta-
bolic manipulation as a treatment for heart failure, even
in the absence of coronary artery disease. PCr/ATP ratio
has been shown to correlate with mortality, and an
improvement in this index may also lead to an improved
survival in this patient population.
Until now, the proposed mechanism of perhexiline is
based on in vitro and animal work. By showing an
increase in R/Q we can support the hypothesis of
increased carbohydrate metabolism as a result of per-
hexiline therapy.
Improvement in mechanical efficiency would reveal
that the above changes contribute, at least in part, to a
direct improvement in cardiac function.
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